Filing Details

Accession Number:
0001437749-20-001950
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-06 20:45:03
Reporting Period:
2020-02-04
Accepted Time:
2020-02-06 20:45:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
834365 Biolife Solutions Inc BLFS Electromedical & Electrotherapeutic Apparatus (3845) 943076866
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1676166 James Mathers C/O Biolife Solutions, Inc.
3303 Monte Villa Parkway, Suite 310
Bothell WA 98021
Chief Revenue Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-02-04 2,113 $1.64 19,497 No 4 M Direct
Common Stock Disposition 2020-02-04 2,113 $14.03 17,384 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option Disposition 2020-02-04 2,113 $0.00 2,113 $1.64
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2019-03-01 2021-12-20 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2019.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.03, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. The reporting person's Form 4 filed on January 23, 2019 reported a remainder of 2,613 derivative securities when in fact the remainder was 2,113 derivative securities beneficially owned by the reporting person.